KeyCorp Research Analysts Lift Earnings Estimates for INSP

Inspire Medical Systems, Inc. (NYSE:INSP) – Equities research analysts at KeyCorp upped their FY2025 EPS estimates for Inspire Medical Systems in a research report issued on Sunday, January 25th. KeyCorp analyst B. Fishbin now expects that the company will post earnings per share of $1.63 for the year, up from their previous forecast of $1.57. KeyCorp currently has a “Sector Weight” rating on the stock. The consensus estimate for Inspire Medical Systems’ current full-year earnings is $2.16 per share. KeyCorp also issued estimates for Inspire Medical Systems’ Q4 2025 earnings at $0.70 EPS and FY2026 earnings at $1.81 EPS.

Several other analysts also recently issued reports on INSP. Truist Financial downgraded Inspire Medical Systems from a “buy” rating to a “hold” rating and set a $96.00 price objective on the stock. in a research report on Thursday, January 22nd. Stifel Nicolaus set a $110.00 price target on shares of Inspire Medical Systems and gave the stock a “buy” rating in a research report on Monday, November 24th. Morgan Stanley reaffirmed an “equal weight” rating and set a $130.00 price target (up previously from $105.00) on shares of Inspire Medical Systems in a research note on Tuesday, December 2nd. Piper Sandler boosted their price objective on shares of Inspire Medical Systems from $135.00 to $165.00 and gave the company an “overweight” rating in a research note on Monday, December 8th. Finally, Evercore ISI reaffirmed an “outperform” rating and set a $125.00 price target on shares of Inspire Medical Systems in a research report on Thursday, January 22nd. Eight equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $133.47.

Inspire Medical Systems Price Performance

INSP stock opened at $81.72 on Wednesday. Inspire Medical Systems has a 12 month low of $70.77 and a 12 month high of $203.12. The firm has a market capitalization of $2.37 billion, a PE ratio of 55.59, a P/E/G ratio of 8.28 and a beta of 0.72. The company’s 50 day simple moving average is $105.96 and its 200-day simple moving average is $95.87.

Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings results on Monday, November 3rd. The company reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.53. The business had revenue of $224.50 million during the quarter, compared to the consensus estimate of $220.39 million. Inspire Medical Systems had a return on equity of 9.41% and a net margin of 5.05%.The business’s revenue was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.60 EPS.

Insider Transactions at Inspire Medical Systems

In other Inspire Medical Systems news, Director Shawn Mccormick sold 2,000 shares of the business’s stock in a transaction on Friday, November 28th. The shares were sold at an average price of $127.48, for a total value of $254,960.00. Following the transaction, the director owned 26,046 shares in the company, valued at $3,320,344.08. The trade was a 7.13% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 2.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Texas Permanent School Fund Corp grew its position in Inspire Medical Systems by 42.2% in the 2nd quarter. Texas Permanent School Fund Corp now owns 40,042 shares of the company’s stock worth $5,196,000 after purchasing an additional 11,892 shares during the last quarter. Y Intercept Hong Kong Ltd boosted its position in shares of Inspire Medical Systems by 553.1% during the third quarter. Y Intercept Hong Kong Ltd now owns 99,049 shares of the company’s stock worth $7,349,000 after buying an additional 83,883 shares during the period. Nordea Investment Management AB bought a new position in Inspire Medical Systems in the 2nd quarter worth approximately $1,634,000. CW Advisors LLC increased its holdings in shares of Inspire Medical Systems by 45.3% during the second quarter. CW Advisors LLC now owns 49,960 shares of the company’s stock valued at $6,484,000 after purchasing an additional 15,576 shares during the period. Finally, Capital Fund Management S.A. raised its stake in shares of Inspire Medical Systems by 44.1% during the second quarter. Capital Fund Management S.A. now owns 68,663 shares of the company’s stock valued at $8,910,000 after purchasing an additional 21,021 shares in the last quarter. Institutional investors and hedge funds own 94.91% of the company’s stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.